Immunis.AI closes on funding for immunogenomic platform

2019 08 05 19 10 8249 Dollar Sign 400

Immunis.AI recently closed on additional financing that brings its total raised to $40 million to date for the ongoing development of its immunogenomic platform.

The company said the funding will support further validation and commercialization of the company's prostate cancer molecular test and will expand development of new tests in breast, colon, lung cancer, and other cancers.

Page 1 of 7
Next Page